Vir Biotechnology, Inc. VIR.MX Stock
Vir Biotechnology, Inc. Price Chart
Vir Biotechnology, Inc. VIR.MX Financial and Trading Overview
| Vir Biotechnology, Inc. stock price | 172 MXN |
| Previous Close | 420 MXN |
| Open | 0 MXN |
| Bid | 0 MXN x N/A |
| Ask | 0 MXN x N/A |
| Day's Range | 420 - 420 MXN |
| 52 Week Range | 383 - 600 MXN |
| Volume | 0 MXN |
| Avg. Volume | 0 MXN |
| Market Cap | 67.04B MXN |
| Beta (5Y Monthly) | 0.255044 |
| PE Ratio (TTM) | 2.5386846 |
| EPS (TTM) | -78.11 MXN |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
VIR.MX Valuation Measures
| Enterprise Value | 54.15B MXN |
| Trailing P/E | 2.5386846 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 150.21828 |
| Price/Book (mrq) | 28.542303 |
| Enterprise Value/Revenue | 121.33 |
| Enterprise Value/EBITDA | -196.147 |
Trading Information
Vir Biotechnology, Inc. Stock Price History
| Beta (5Y Monthly) | 0.255044 |
| 52-Week Change | 0% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 600 MXN |
| 52 Week Low | 383 MXN |
| 50-Day Moving Average | 420 MXN |
| 200-Day Moving Average | 423.34 MXN |
VIR.MX Share Statistics
| Avg. Volume (3 month) | 0 MXN |
| Avg. Daily Volume (10-Days) | 0 MXN |
| Shares Outstanding | 133.98M |
| Float | 86.5M |
| Short Ratio | N/A |
| % Held by Insiders | 14.24% |
| % Held by Institutions | 73.82% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -32.19% |
| Operating Margin (ttm) | -64.29% |
| Gross Margin | -26.13% |
| EBITDA Margin | -61.85% |
Management Effectiveness
| Return on Assets (ttm) | -6.45% |
| Return on Equity (ttm) | -7.23% |
Income Statement
| Revenue (ttm) | 446.3M MXN |
| Revenue Per Share (ttm) | 3.36 MXN |
| Quarterly Revenue Growth (yoy) | -94.89% |
| Gross Profit (ttm) | 1.03B MXN |
| EBITDA | -276062016 MXN |
| Net Income Avi to Common (ttm) | -143684000 MXN |
| Diluted EPS (ttm) | 165.44 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.25B MXN |
| Total Cash Per Share (mrq) | 16.8 MXN |
| Total Debt (mrq) | 128.73M MXN |
| Total Debt/Equity (mrq) | 6.53 MXN |
| Current Ratio (mrq) | 4.86 |
| Book Value Per Share (mrq) | 14.715 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 987.38M MXN |
| Levered Free Cash Flow (ttm) | 853.38M MXN |
Profile of Vir Biotechnology, Inc.
| Country | Mexico |
| State | CA |
| City | San Francisco |
| Address | 499 Illinois Street |
| ZIP | 94158 |
| Phone | 415 906 4324 |
| Website | https://www.vir.bio |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 576 |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Q&A For Vir Biotechnology, Inc. Stock
What is a current VIR.MX stock price?
Vir Biotechnology, Inc. VIR.MX stock price today per share is 172 MXN.
How to purchase Vir Biotechnology, Inc. stock?
You can buy VIR.MX shares on the Mexico exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Vir Biotechnology, Inc.?
The stock symbol or ticker of Vir Biotechnology, Inc. is VIR.MX.
Which industry does the Vir Biotechnology, Inc. company belong to?
The Vir Biotechnology, Inc. industry is Biotechnology.
How many shares does Vir Biotechnology, Inc. have in circulation?
The max supply of Vir Biotechnology, Inc. shares is 135.03M.
What is Vir Biotechnology, Inc. Price to Earnings Ratio (PE Ratio)?
Vir Biotechnology, Inc. PE Ratio is now.
What was Vir Biotechnology, Inc. earnings per share over the trailing 12 months (TTM)?
Vir Biotechnology, Inc. EPS is -78.11 MXN over the trailing 12 months.
Which sector does the Vir Biotechnology, Inc. company belong to?
The Vir Biotechnology, Inc. sector is Healthcare.